Wilms' Tumor

Many children with cancer experience emotional distress, fatigue, and difficulties in relationships. Their parents also face increased responsibilities and may feel more distressed and tired. While psychological interventions for these families have shown promise in improving social skills, coping, and well-being, further research is needed. Hypnosis is commonly used in pediatric oncology to reduce pain and distress during procedures and has also been effective in enhancing well-being in adults with cancer. This trial explores the feasibility and potential benefits of combining self-care and hypnosis in a group setting for children with cancer and their parents. The intervention involves six monthly group sessions, each lasting two hours, where participants learn self-hypnosis exercises and discuss self-care techniques like understanding personal needs, self-respect, assertiveness, and managing negative thoughts. Homework assignments are given to encourage positive changes. Two groups participate: one including children with cancer and their siblings, and another for their parents. Data are collected before and after the intervention through questionnaires and interviews to assess its impact. Participants will complete assessments measuring changes in children's quality of life, fatigue related to cancer, and parents' perceptions of their child's quality of life and their own fatigue. Secondary outcomes include the impact of cancer on the family, parents' emotional distress, and coping strategies. These are evaluated before the program starts and immediately after its conclusion at six months. The study aims to improve understanding of how this combined self-care and hypnosis intervention may enhance the well-being of children with cancer and their families.

Sleep plays a vital role in a child's development, affecting brain function, emotional health, and overall recovery. Children undergoing intensive cancer treatments often experience sleep problems such as difficulty falling or staying asleep, shorter sleep duration, or poor sleep quality. These issues, reported in a significant portion of pediatric cancer survivors, can impact treatment adherence, daily life, and social interactions, highlighting the need for better sleep management in this group. Researchers are evaluating the Dreamcatchers Programme, a nurse-led, multi-component intervention designed to improve sleep quality in children with cancer. The program involves sleep hygiene education, progressive muscle relaxation (PMR), and breathing exercises, delivered through group sessions and weekly follow-ups over four weeks. The intervention group receives these targeted strategies, while the control group continues routine hospital support without sleep-specific content, with access to the program after the study. Participants will attend initial education sessions, practice relaxation techniques, and keep sleep diaries to track habits and progress. Nurses will monitor sleep quality and overall life quality at three months using validated tools. Data will be collected securely and confidentiality maintained. This pilot study aims to assess feasibility and provide preliminary effectiveness results to guide future pediatric oncology sleep care.

Researchers are evaluating the safety, tolerability, and efficacy of CBA-1205, an anti-DLK1 monoclonal antibody, in patients with advanced solid tumors including hepatocellular carcinoma, malignant melanoma, and certain pediatric cancers. This first-in-human, Phase I, multi-center, non-randomized, open-label study is designed in five parts to assess these outcomes in different patient groups, especially those who have no standard treatment options or are intolerant or non-responsive to existing therapies. The study treatment involves intravenous administration of CBA-1205 at varying doses depending on the study part. In Part 1, doses from 0.1 to 30 mg/kg are given every two weeks in 28-day cycles to patients with solid tumors. Parts 2 through 5 administer doses ranging from 10 to 30 mg/kg every two weeks in similar 28-day cycles to patients with hepatocellular carcinoma, malignant melanoma, and pediatric cancers, continuing until criteria for treatment discontinuation are met. Participants will undergo safety and tolerability evaluations, including monitoring for dose-limiting toxicity during the first 28 days and adverse events up to 12 months. Pharmacokinetic and immunogenicity analyses will be conducted from Day 1 to Day 43 or until treatment discontinuation. Efficacy will be assessed at screening and regular intervals during treatment. The study includes detailed laboratory tests and performance status assessments, with the total participation duration varying by individual response and treatment continuation.

Researchers are evaluating the SYSUCC-RMS regimen for children with rhabdomyosarcoma, a type of pediatric cancer. This study aims to understand how effective and safe this treatment is, while also exploring how combining radiotherapy with chemotherapy affects survival rates across different risk groups: low, medium, high, and very high risk. The study is a Phase 3 clinical trial led by Yizhuo Zhang. Participants receive one of several combination chemotherapy regimens based on their risk level: low risk patients receive VAC, intermediate risk patients receive VAC/VII, high risk patients receive CAV/IE, and very high risk patients receive CAV/VIP. The study follows a single-arm design and evaluates the treatments over various risk groups, focusing on the impact of concurrent therapies on survival. During the study, researchers will monitor participants for up to 10 years, assessing outcomes such as objective response rate, disease control rate, progression-free survival, and overall survival. Safety of the SYSUCC-RMS regimen will also be tracked throughout this period. Participants’ health status will be regularly evaluated to understand the long-term effects and treatment outcomes.

Researchers are evaluating how well combination chemotherapy works in treating patients with newly diagnosed stages 2 to 4 diffuse anaplastic Wilms tumor (DAWT) and patients with relapsed favorable histology Wilms tumor (FHWT). This phase II trial compares the effects of two chemotherapy regimens, UH-3 and ICE/Cyclo/Topo, on event-free survival and overall survival, aiming to improve outcomes based on different relapse risk groups and prior treatments. The study also explores kidney toxicity, genetic markers, surgery impacts, and radiation therapy techniques to reduce side effects and better understand tumor behavior. Participants are assigned to one of two treatment groups. In Arm I (Regimen UH-3), patients receive cycles of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan intravenously over various days in a 21-day cycle, with radiation therapy at week 7 of cycle 3 if needed. In Arm II (Regimen ICE/Cyclo/Topo), patients receive cycles of carboplatin, etoposide, ifosfamide, cyclophosphamide, and topotecan intravenously over 10 cycles every 21 days, with surgery and/or radiation therapy during certain cycles as clinically indicated. Throughout the trial, patients undergo multiple imaging tests including CT scans, PET scans, chest x-rays, MRIs, abdominal ultrasounds, and bone scans, along with blood sample collections and biopsies. After completing treatment, follow-up visits occur every 3 months for the first 2 years, then every 6 months for years 3 and 4, and once at year 5. The main outcomes measured are event-free survival and overall survival up to 5 years from study entry, with ongoing monitoring for treatment effects and safety.

Researchers are evaluating selinexor as a potential treatment for people with relapsed or refractory Wilms tumor, rhabdoid tumor, malignant peripheral nerve sheath tumors (MPNST), BCOR-driven sarcomas, or other solid tumors that produce higher than normal levels of the XPO1 protein or have genetic changes that increase XPO1 activity. This phase II study aims to understand selinexor's effectiveness in these specific pediatric solid tumors, sponsored by Memorial Sloan Kettering Cancer Center. The study treats participants with selinexor at a pediatric recommended phase 2 dose of 35 mg/m2 once weekly using a liquid form, with a maximum dose of 100 mg per dose. Participants are divided into cohorts based on their tumor type, including Wilms tumor, rhabdoid tumor, MPNST, other solid tumors showing potential benefit from selinexor, and BCOR-driven sarcomas. Each cohort follows the same treatment schedule, and some patients may be enrolled in pharmacokinetic cohorts depending on their age. During the study, participants will undergo assessments to monitor their disease status, including measurable disease evaluations using standardized criteria. Researchers will track the overall response rate six months after treatment begins to determine the treatment's impact. Participants must meet specific health criteria, including adequate organ function and performance status. The study includes informed consent, safety monitoring, and follows participants until the end of the treatment period, which may last several months.

Researchers are studying children aged 5 to 18 years who have solid cancer or blood-related cancers to understand how intense physical activities or stretching affect insulin sensitivity and other metabolic, motor, and nutritional factors. The study aims to observe whether intense physical activity improves these health measures compared to a stretching program. Children are included at the start of their cancer treatment, with a focus on their first treatment experience and a life expectancy exceeding six months. The study involves two different physical activity programs lasting six months: one intense adapted physical activity combining aerobics and muscle strengthening, and another stretching program. Children participate in sessions two to three times a week, either during hospital stays or via videoconference at home. The intense activity sessions last 30 minutes for younger children and 60 minutes for older children. Evaluations occur at the beginning, at three and six months during the program, and follow-ups are done six and eighteen months after the programs end. Participants will undergo metabolic, motor, and nutritional assessments at scheduled time points throughout the study and after completion. The research team will monitor insulin sensitivity as the main outcome. Children receive personalized physical activity sessions adapted to their abilities and preferences. The overall participation lasts up to about two years, including initial treatment and follow-up evaluations to track the long-term effects of the physical activity programs.

This research aims to understand how follow-up care is managed for survivors of childhood cancer in Switzerland as they move from pediatric to adult healthcare. It focuses on adolescent and young adult survivors who have completed cancer treatment and are living with potential late effects. The study compares three different transition models to find out which best meets survivors' needs and helps maintain regular follow-up care. Participants are part of a multicenter study involving three pediatric oncology centers in Switzerland. Survivors receive questionnaires about their cancer knowledge, worries, self-management skills, ongoing care, and expectations related to their follow-up care. Questionnaires are sent before and after their transition to adult care, with follow-ups at three and fifteen months to track changes over time. During the study, participants complete several questionnaires assessing their readiness for transition and knowledge about their cancer history. The study measures cancer worry, self-management, ongoing care needs, and expectations at baseline, three months, and fifteen months. Data helps improve transition strategies, aiming for better adherence to adult follow-up care. The total participation time covers these assessments over more than a year, supporting long-term survivor care.

Researchers are studying how Antimüllerian Hormone (AMH) levels can predict the risk of future infertility in girls aged 3 to 14 who are undergoing cancer treatment or treatment for benign diseases. The goal is to identify young patients who may have a reduced ovarian reserve after treatment and could benefit from special follow-up or fertility preservation. The study includes children at high, moderate/low, or no risk of ovarian damage from chemotherapy or pelvic irradiation. The study observes AMH and other hormone levels before and after treatment, with no interventions applied. Participants are grouped by their risk level: high risk patients receiving conditioning therapy or pelvic irradiation; moderate/low risk patients treated with chemotherapy regimens for various cancers; and a control group with no risk, consisting of patients with benign diseases or cancers not requiring gonadotoxic treatment. Assessments occur at diagnosis, treatment end, and during follow-up visits scheduled yearly for three years, then every two years until age 18. Participants will have their ovarian reserve evaluated through hormone tests including AMH, FSH, estradiol, testosterone, and LH, alongside menstrual cycle tracking and pubertal development assessed annually using Tanner staging and bone age X-rays. The primary outcome is the AMH marker measured regularly up to 18 years old. Secondary outcomes include premature ovarian failure and ovarian reserve changes. The study also monitors oncological outcomes as per standard care, with a total follow-up duration extending to 18 years old.

Researchers are evaluating the immune changes in tumors, blood, and bone marrow following the infusion of somatic cell therapy drugs in patients with solid tumors or hematologic cancers. The study aims to identify specific phenotypic, transcriptional, and epigenetic profiles of immune cells within tumors and correlate these profiles with clinical responses and potential toxicities. This research is designed to explore how different cellular components respond to adoptive cell therapy over time. Participants will undergo several procedures including three tumor biopsies taken at baseline, day 15, and optionally at relapse. Blood samples will be collected seven times at key intervals before and after treatment, including at day -7, day 0, day 3, day 7, day 15, month 3, and at relapse. If bone marrow biopsies or aspirations are done as part of routine care, additional samples will be taken for analysis. During the study, researchers will monitor immune cell changes using spectral flow cytometry and RNA sequencing three months after therapy infusion. They will also evaluate objective response at three months, and track progression-free and overall survival over five years. Safety of biopsy procedures will be assessed from enrollment until 30 days after the last sample. Participants are expected to comply with protocol requirements and provide informed consent, with total participation varying based on individual treatment and follow-up.